Which cervical and endometrial cancer patients will benefit most from intensity-modulated proton therapy?

van de Sande, MAE
Creutzberg, CL
Water, Steven
Sharfo, Abdul
Hoogeman, Mischa

Open link

Publication date

January 2016

DOI

10.1016/j.radonc.2016.06.016

Publisher

Elsevier BV

Abstract

In this dosimetric comparison study it was shown that IMPT with robust planning reduces dose to surrounding organs in cervical and endometrial cancer treatment compared with IMRT. Especially for the para-aortic region, clinically relevant dose reductions were obtained for kidneys, spinal cord and bowel, justifying the use of proton therapy for this indication. (C) 2016 Elsevier Ireland Ltd. All rights reserved

Extracted data

We use cookies to provide a better user experience.

Data Protection

Which cervical and endometrial cancer patients will benefit most from intensity-modulated proton therapy?

Abstract

Extracted data

Which cervical and endometrial cancer patients will benefit most from intensity-modulated proton therapy?

Abstract

Extracted data

Related items

Related items